WNK1 inhibitors

Abstract

The present invention relates to novel compounds of formula (I), pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of WNK1. Formula (I)

Claims

 1. A compound of formula (I):Formula (I)whereinY is C(H) or N;W is C(H)2 or C(D)2;R1is H, C1-3 alkyl or cyclopropylR2is H; C1-3 alkyl optionally substituted with OH; or C3-5 cycloalkyl; R3 is H; C1-3 alkyl optionally substituted with OH; -OC1-3 alkyl optionally substituted with one or more F; -C(O)NHCH3; -NH2; -N(H)(CH3); -N(CH3)2; or halogen; R4 is H, C1-4 alkyl, or C3-5 cycloalkyl; A is selected from the group consisting of H, C1-3 alkoxy, CF3, and a group of formula (II):Formula (II)wherein X is C(H) or N;R6 is H or C1-4 alkyl; and R5is selected from the group consisting of C1-6 alkyl optionally substituted with one or more, identical or different, substituents R7, wherein one or more methylene(s) of said C1-6 alkyl is optionally and individually replaced with -O- or C=O; C3-6 cycloalkyl optionally substituted with one or more, identical or different, substituents R7; and tetrahydropyranyl; wherein two R7 are optionally linked together to form a ring together with the intervening atom(s); R7 is individually selected from C1-3 alkoxy optionally substituted with one or more F; -OH; -O-benzyl; C1-3 alkyl optionally substituted with OH; N(CH3)2; N(H)2; ; and ; or when two R7 are linked together to form a ring, then said two R7 are individually selected from C1-2 alkanediyl optionally substituted with one or two substituents selected from F and OH, and one of the methylene of said C1-2 alkanediyl is optionally replaced with -O-; orR5 and R6 are linked together to form a ring andR5is a bond or C1-5 alkanediyl optionally substituted with one or more, identical or different, substituents R8, and one methylene of the C1-5 alkanediyl is optionally replaced with -O- or N(R9); andR6is a bond or C1-5 alkanediyl optionally substituted with one or more, identical or different, substituents R8, and one methylene of the C1-5 alkanediyl is optionally replaced with -O- or N(R9); wherein two R8 are optionally linked together to form a ring together with the intervening atom(s); R8 is individually selected from C1-3 alkyl optionally substituted with OH; -OH; -F; -N(H)2; and -OC1-3 alkyl optionally substituted with one or more F; or when two R8 are linked together to form a ring, then said two R8 are individually selected from C1-3 alkanediyl optionally substituted with one or two substituents selected from F, OH, and NH2, and one or two methylene(s) of said C1-3 alkanediyl is optionally and individually replaced with -O-, -N(H)- or -N(CH3)-; andR9 is H, C1-3 alkyl, oxetanyl, or , or a pharmaceutically acceptable salt thereof, with the proviso that the compound is not N-[(2,3,5-Trimethyl-1H-indol-7-yl)methyl]-2-quinoxalinamine.  2. The compound according to claim 1, wherein the compound is of Formula (Ia), Formula (Ib), Formula (Ic), or Formula (Id):Formula (Ia)Formula (Ib)Formula (Ic),Formula (Id). 3. The compound according to anyone of the preceding claims, wherein R1 is H, CH3, or isopropyl, R2 is H, CH3, cyclopropyl, or CH2OH and R3 is H, CH3, CH2OH, NH2, N(CH3)2, Cl, C(O)NHCH3, OCHF2, or OCH3.  4. The compound according to anyone of the preceding claims, wherein the compound is of Formula (Ib), and wherein R1 is H, R2 is H, and R3 is H, CH3, or OCH3.  5. The compound according to anyone of the preceding claims, wherein the compound is of Formula (Ic), and wherein R1 is CH3, R2 is H, and R3 is H, N(CH3)2, Cl, CH2OH, OCHF2, C(O)NHCH3 or OCH3.  6. The compound according to anyone of the preceding claims, wherein the compound is of Formula (Ib), and wherein R1 is H, R2 is CH3, cyclopropyl, or CH2OH, and R3 is H.  7. The compound according to anyone of the preceding claims, wherein the compound is of Formula (Ic), and wherein R1 is isopropyl, R2 is H, and R3 is H or OCH3.  8. The compound according to anyone of the preceding claims, wherein R4 is H or CH3.  9. The compound according to anyone of the preceding claims, wherein A is H, CF3 or of Formula (II): Formula (II)wherein X is N;R6 is H or C1-4 alkyl; and R5 is selected from the group consisting of C1-6 alkyl optionally substituted with one or more, identical or different, substituents R7, wherein one or more methylene(s) of said C1-6 alkyl is optionally and individually replaced with -O- or C=O; C3-6 cycloalkyl optionally substituted with one or more, identical or different, substituents R7; and tetrahydropyranyl; wherein two R7 are optionally linked together to form a ring together with the intervening atom(s); and R7 is individually selected from C1-3 alkoxy optionally substituted with one or more F; -OH; -O-benzyl; C1-3 alkyl optionally substituted with OH; N(CH3)2; N(H)2; ; and ; or when two R7 are linked together to form a ring, then said two R7 are individually selected from C1-2 alkanediyl optionally substituted with one or two substituents selected from F and OH, and one of the methylene of said C1-2 alkanediyl is optionally replaced with -O-.  10. The compound according to anyone of the preceding claims, wherein R6 is H or CH3.   11. The compound according to anyone of the preceding claims, wherein R5 is C1 alkyl substituted with one or more, identical or different, substituents R7, C2 alkyl substituted with one or more, identical or different, substituents R7, C3 alkyl substituted with one or more, identical or different, substituents R7, C4 alkyl substituted with one or more, identical or different, substituents R7, C5 alkyl substituted with one or more, identical or different, substituents R7, C6 alkyl substituted with one or more, identical or different, substituents R7, is C4 cycloalkyl substituted with one or more, identical or different, substituents R7, C6 cycloalkyl, or C6 cycloalkyl substituted with one or more, identical or different, substituents R7.  12. The compound according to anyone of the preceding claims, wherein R7 is OH, N(H)2, N(CH3)2, OCH3, OCHF2, CH3, CH2OH, or .  13. The compound according to anyone of the preceding claims, wherein A is piperidinyl, pyrrolidinyl, azetidinyl, piperazinyl, or morpholinyl, wherein said piperidinyl, pyrrolidinyl, azetidinyl, or piperazinyl is optionally substituted with one or more individually selected R18, wherein two R18 are optionally linked together to form a ring together with the intervening atom(s); and wherein said morpholinyl optionally substituted with one or more, identical or different, substituents R19, wherein R19 is individually selected from C1-3 alkyl and C1-3 alkyl substituted with OH;R18 is individually selected from C1-3 alkyl optionally substituted with OH; -OH; F; N(H)2; and -OC1-3 alkyl optionally substituted with one or more F; or when two R18 are linked together to form a ring, then said two R18 are individually selected from C1-3 alkanediyl optionally substituted with one or two substituents selected from F, OH, and NH2, and one or two methylene(s) of said C1-3 alkanediyl is optionally and individually replaced with -O-, -N(H)- or -N(CH3)-.   14. The compound according to anyone of the preceding claims, wherein A is piperidinyl, pyrrolidinyl, azetidinyl, or piperazinyl, wherein said piperidinyl, pyrrolidinyl, azetidinyl, or piperazinyl is optionally substituted with one or more individually selected R18, wherein R18 is -CH3, -CH2OH, -OH, N(H)2, OCHF2, -F, oxetanyl or .  15. The compound according to anyone of the preceding claims, wherein A is piperidinyl, pyrrolidinyl, azetidinyl or piperazinyl, wherein said piperidinyl, pyrrolidinyl, azetidinyl, or piperazinyl is substituted with two or more R18, wherein two R18 are linked together to form a ring together with the intervening atom(s), and wherein the two R18 linked together to form a ring are individually selected from C1-3 alkanediyl optionally substituted with one or two substituents selected from F, OH and -NH2, and wherein one or two methylene(s) of said C1-3 alkanediyl is optionally and individually replaced with -O-, -N(H)- or -N(CH3)-.  16. The compound according to anyone of the preceding claims, wherein A is morpholinyl, wherein said morpholinyl optionally substituted with one or more, identical or different, substituents R19, wherein R19 is -CH3, or -CH2OH.  17. The compound according to anyone of the preceding claims, wherein A is selected from the group consisting of: H, CF3,      18. The compound according to anyone of the preceding claims, wherein the compound is selected from the group consisting of: 7-cyclopropyl-N-(1H-indol-6-ylmethyl)quinoxalin-2-amine,N-[(7-methyl-1H-indol-5-yl)methyl]quinoxalin-2-amine,N-(1H-indol-6-ylmethyl)-7-(piperidin-1-yl)quinoxalin-2-amineN-(1H-indol-5-ylmethyl)quinoxalin-2-amine,1-(3-{[(6-amino-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol,N-(1H-indol-4-ylmethyl)-6-{2-methyl-2,7-diazaspiro[3.5]nonan-7-yl}pyrido[2,3-b]pyrazin-3-amine1-[3-({[7-(hydroxymethyl)-3-methyl-1H-indol-4-yl]methyl}amino)pyrido[2,3-b]pyrazin-6-yl]piperidin-4-ol,1-(3-{[1H-indol-4-yl(²H₂)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol,N-(1H-indol-6-ylmethyl)-6-(piperidin-4-yl)pyrido[2,3-b]pyrazin-3-amine,[6-({[6-(piperidin-1-yl)pyrido[2,3-b]pyrazin-3-yl]amino}methyl)-1H-indol-2-yl]MeOH,N-[(3-isopropyl-7-methoxy-1H-indol-4-yl)methyl]-6-(pyrrolidin-1-yl)pyrido[2,3-b]pyrazin-3-amine,6-N-cyclohexyl-3-N-[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]pyrido[2,3-b]pyrazine-3,6-diamine,1-[3-({[7-(dimethylamino)-3-methyl-1H-indol-4-yl]methyl}amino)pyrido[2,3-b]pyrazin-6-yl]piperidin-4-ol,6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-N-[(3-methyl-1H-indol-4-yl)methyl]pyrido[2,3-b]pyrazin-3-amine,N,3-dimethyl-4-{[(6-{methyl[(1s,3s)-3-hydroxycyclobutyl]amino}pyrido[2,3-b]pyrazin-3-yl)amino]methyl}-1H-indole-7-carboxamide,1-[3-({[7-(difluoromethoxy)-3-methyl-1H-indol-4-yl]methyl}amino)pyrido[2,3-b]pyrazin-6-yl]piperidin-4-ol,3-(hydroxymethyl)-1-(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol,1-(3-{[(7-chloro-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol, [(3R)-1-(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)pyrrolidin-3-yl]methanol, (3R)-1-(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)pyrrolidin-3-ol,cis-(1s,3s)-3-[(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)amino]cyclobutan-1-ol, N-[(1H-indol-6-yl)methyl]-6-{2-oxa-6-azaspiro[3.3]heptan-6-yl}pyrido[2,3-b]pyrazin-3-amine, 6-{2,6-diazaspiro[3.3]heptan-2-yl}-N-(1H-indol-6-ylmethyl)pyrido[2,3-b]pyrazin-3-amine, 3-(hydroxymethyl)-1-(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol, [(3R)-1-(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-3-yl]methanol, N-[(1H-indol-6-yl)methyl]pyrido[2,3-b]pyrazin-3-amine, cis-(1R,3R)-3-({3-[(1H-indol-6-ylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl}amino)cyclobutan-1-ol, [4-(hydroxymethyl)-1-(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-yl]methanol, 3-N-[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]-6-N-[trans-4-aminocyclohexyl]pyrido[2,3-b]pyrazine-3,6-diamine, 7-tert-butyl-N-(1H-indol-6-ylmethyl)quinoxalin-2-amine, N-[(1H-indol-6-yl)methyl]-6-(piperidin-1-yl)pyrido[2,3-b]pyrazin-3-amine, [4-(hydroxymethyl)-1-{3-[(1H-indol-6-ylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl}piperidin-4-yl]methanol, N-(1H-indol-6-ylmethyl)-6-[4-(oxetan-3-yl)piperazin-1-yl]pyrido[2,3-b]pyrazin-3-amine, 7-{3-[(1H-indol-6-ylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl}-7-azaspiro[3.5]nonan-2-amine, 1-{3-[({1H-pyrrolo[2,3-b]pyridin-5-yl}methyl)amino]pyrido[2,3-b]pyrazin-6-yl}piperidin-4-ol, 3-N-(1H-indol-6-ylmethyl)-6-N-(oxan-4-yl)pyrido[2,3-b]pyrazine-3,6-diamine, [(2R)-4-(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)morpholin-2-yl]methanol,N-[(1H-indol-6-yl)methyl]-6-(pyrrolidin-1-yl)pyrido[2,3-b]pyrazin-3-amine,7-ethyl-N-[(1H-indol-6-yl)methyl]quinoxalin-2-amine,N-(1H-indol-6-ylmethyl)-6-{2-methyl-2,7-diazaspiro[3.5]nonan-7-yl}pyrido[2,3-b]pyrazin-3-amine, 1-(3-{[(3-hydroxy-4-methoxyphenyl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol,1-(3-{[(1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol,6-{2,7-diazaspiro[3.5]nonan-7-yl}-N-[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]pyrido[2,3-b]pyrazin-3-amine,N-[(1H-indol-6-yl)methyl]-7-methylquinoxalin-2-amine,3-N-(1H-indol-6-ylmethyl)-6-N-{2-oxaspiro[3.3]heptan-6-yl}pyrido[2,3-b]pyrazine-3,6-diamine,N-[(2-methyl-1H-indol-5-yl)methyl]quinoxalin-2-amine,6-{2,6-diazaspiro[3.4]octan-6-yl}-N-(1H-indol-6-ylmethyl)pyrido[2,3-b]pyrazin-3-amine,N3-[(1H-indol-6-yl)methyl]-N6-[trans-4-(difluoromethoxy)cyclohexyl]pyrido[2,3-b]pyrazine-3,6-diamine,N-(1H-indol-6-ylmethyl)-6-(morpholin-4-yl)pyrido[2,3-b]pyrazin-3-amine,(3R)-1-{3-[(1H-indol-6-ylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl}piperidin-3-ol,N-[(1H-indol-6-yl)methyl]-6-{2-oxa-6-azaspiro[3.4]octan-6-yl}pyrido[2,3-b]pyrazin-3-amine,N-(1H-indol-6-ylmethyl)-6-{1-oxa-9-azaspiro[5.5]undecan-9-yl}pyrido[2,3-b]pyrazin-3-amine,[(2R)-4-[3-({[7-(difluoromethoxy)-3-methyl-1H-indol-4-yl]methyl}amino)pyrido[2,3-b]pyrazin-6-yl]morpholin-2-yl]methanol,6-N-cyclohexyl-3-N-(1H-indol-6-ylmethyl)pyrido[2,3-b]pyrazine-3,6-diamine,1-(3-{[(3-isopropyl-7-methoxy-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol,(3R,4R)-3-(hydroxymethyl)-1-{3-[(1H-indol-6-ylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl}piperidin-4-ol,[(2R)-4-{3-[(1H-indol-6-ylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl}morpholin-2-yl]methanol,N-(1H-indol-6-ylmethyl)-6-{3-oxa-9-azaspiro[5.5]undecan-9-yl}pyrido[2,3-b]pyrazin-3-amine,trans-4-({3-[(1H-indol-6-ylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl}amino)cyclohexan-1-ol,1-(3-{[(2-cyclopropyl-1H-indol-5-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol,N6-[2-(dimethylamino)ethyl]-N3-[(1H-indol-6-yl)methyl]pyrido[2,3-b]pyrazine-3,6-diamine,6-{2,7-diazaspiro[3.5]nonan-7-yl}-N-(1H-indol-6-ylmethyl)pyrido[2,3-b]pyrazin-3-amine,3-[(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)amino]propane-1,2-diol,[(3S)-1-(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-3-yl]methanol,1-(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol,(1-{3-[(1H-indol-6-ylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl}piperidin-4-yl)methanol,trans-4-[methyl(3-{[(3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)amino]cyclohexan-1-ol,N-[(1H-indol-6-yl)methyl]quinoxalin-2-amine,1-(3-{[(7-methoxy-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol,(3S)-1-(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-3-ol,1-(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol,N3-[(1H-indol-6-yl)methyl]-N6-(3-methoxypropyl)pyrido[2,3-b]pyrazine-3,6-diamine,trans-3-({3-[(1H-indol-6-ylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl}(methyl)amino)cyclobutan-1-ol,N-[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]-6-{2-methyl-2,7-diazaspiro[3.5]nonan-7-yl}pyrido[2,3-b]pyrazin-3-amine,N-(1H-indol-6-ylmethyl)-6-(piperazin-1-yl)pyrido[2,3-b]pyrazin-3-amine,cis-3-[(3-{[(3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)amino]cyclobutan-1-ol,(3S,4S)-3-(hydroxymethyl)-1-(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol,1-(3-{[(2-methyl-1H-indol-5-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol,N3-[(1H-indol-6-yl)methyl]-N6-[trans-4-aminocyclohexyl]pyrido[2,3-b]pyrazine-3,6-diamine,3-[(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)amino]-2,2-dimethylpropan-1-ol,6-N-{6,6-difluorospiro[3.3]heptan-2-yl}-3-N-(1H-indol-6-ylmethyl)pyrido[2,3-b]pyrazine-3,6-diamine,6-{4-[(1-aminocyclopropyl)carbonyl]piperazin-1-yl}-N-(1H-indol-6-ylmethyl)pyrido[2,3-b]pyrazin-3-amine,6-[cis-2,6-dimethylmorpholin-4-yl]-N-(1H-indol-6-ylmethyl)pyrido[2,3-b]pyrazin-3-amine,[(3S)-1-{3-[(1H-indol-6-ylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl}pyrrolidin-3-yl]methanol,[4-(hydroxymethyl)-1-(3-{[(3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-yl]methanol,cis-3-[(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)(methyl)amino]cyclobutan-1-ol,4-[({6-[(2R)-2-(hydroxymethyl)morpholin-4-yl]pyrido[2,3-b]pyrazin-3-yl}amino)methyl]-N,3-dimethyl-1H-indole-7-carboxamide,N-[(1H-indol-6-yl)methyl]-6-methylquinoxalin-2-amine,1-{3-[(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)amino]propyl}azepan-2-one,1-(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-3-ol,[4-(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)morpholin-2-yl]methanol,N-(1H-indol-6-ylmethyl)-6-(4-methylpiperazin-1-yl)pyrido[2,3-b]pyrazin-3-amine,trans-3-[methyl(3-{[(3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)amino]cyclobutan-1-ol,(3S,4S)-3-(hydroxymethyl)-1-{3-[(1H-indol-6-ylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl}piperidin-4-ol,6-(azetidin-1-yl)-N-[(1H-indol-6-yl)methyl]pyrido[2,3-b]pyrazin-3-amine,1-(3-{[(3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol,(3R,4R)-3-(hydroxymethyl)-1-(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)piperidin-4-ol,6-[(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)amino]spiro[3.3]heptan-2-ol,3-N-[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]-6-N-[trans-4-(dimethylamino)cyclohexyl]pyrido[2,3-b]pyrazine-3,6-diamine,(3S)-1-(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)pyrrolidin-3-ol,trans-3-({3-[(1H-indol-6-ylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl}amino)cyclobutan-1-ol,(3S)-1-(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)pyrrolidin-3-ol,[4-(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)morpholin-2-yl]methanol,(3S)-1-(3-{[(3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)pyrrolidin-3-ol,1-(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)azetidin-3-ol,4-({[6-(4-hydroxypiperidin-1-yl)pyrido[2,3-b]pyrazin-3-yl]amino}methyl)-N,3-dimethyl-1H-indole-7-carboxamide,6-{1,4-dioxa-9-azaspiro[5.5]undecan-9-yl}-N-(1H-indol-6-ylmethyl)pyrido[2,3-b]pyrazin-3-amine,N-(1H-indol-6-ylmethyl)-6-{1-oxa-8-azaspiro[4.5]decan-8-yl}pyrido[2,3-b]pyrazin-3-amine,6-[cis-2,6-dimethylmorpholin-4-yl]-N-[(3-isopropyl-7-methoxy-1H-indol-4-yl)methyl]pyrido[2,3-b]pyrazin-3-amine,6-[(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)amino]spiro[3.3]heptan-2-ol,(3S,4S)-4-(hydroxymethyl)-1-{3-[(1H-indol-6-ylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl}piperidin-3-ol,N-[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]-6-(4-methylpiperazin-1-yl)pyrido[2,3-b]pyrazin-3-amine,N-[(1H-indol-6-yl)methyl]-7-methoxyquinoxalin-2-amine,trans-4-[(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)(methyl)amino]cyclohexan-1-ol,3-[(3-{[(1H-indol-6-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)amino]propan-1-ol,6-N-[4-(dimethylamino)cyclohexyl]-3-N-(1H-indol-6-ylmethyl)pyrido[2,3-b]pyrazine-3,6-diamine,[1-(hydroxymethyl)-4-[(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)amino]cyclohexyl]methanol,1-{3-[(1H-indol-6-ylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl}azetidin-3-amine,[(2R)-4-(3-{[(3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)morpholin-2-yl]methanol,[4-(3-{[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]amino}pyrido[2,3-b]pyrazin-6-yl)-6,6-dimethylmorpholin-2-yl]methanol,N3-[(7-methoxy-3-methyl-1H-indol-4-yl)methyl]-N6-({2-oxabicyclo[2.2.2]octan-3-yl}methyl)pyrido[2,3-b]pyrazine-3,6-diamine,N-[(1H-indol-6-yl)methyl]-7-(trifluoromethyl)quinoxalin-2-amine,6-{2,7-diazaspiro[3.5]nonan-2-yl}-N-(1H-indol-6-ylmethyl)pyrido[2,3-b]pyrazin-3-amine,N-(1H-indol-5-ylmethyl)-6-(morpholin-4-yl)pyrido[2,3-b]pyrazin-3-amine, and6-{3,9-diazaspiro[5.5]undecan-3-yl}-N-[(1H-indol-6-yl)methyl]pyrido[2,3-b]pyrazin-3-amine. 19. The compound according to anyone of the preceding claims, wherein the compound of Formula (I) is a WNK lysine deficient protein kinase 1 (WNK1) inhibitor.   20. A pharmaceutical composition comprising a compound according to claims 1-19, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients and / or diluents.   21. The compound according to any one of claims 1-19, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 20, for use as a medicament.  22. A compound of formula (I):Formula (I)whereinY is C(H) or N;W is C(H)2 or C(D)2;R1is H, C1-3 alkyl or cyclopropylR2is H; C1-3 alkyl optionally substituted with OH; or C3-5 cycloalkyl; R3 is H; C1-3 alkyl optionally substituted with OH; -OC1-3 alkyl optionally substituted with one or more F; -C(O)NHCH3; -NH2; -N(H)(CH3); -N(CH3)2; or halogen; R4 is H, C1-4 alkyl, or C3-5 cycloalkyl; A is selected from the group consisting of H, C1-3 alkoxy, CF3, and a group of formula (II):Formula (II)wherein X is C(H) or N;R6 is H or C1-4 alkyl; and R5is selected from the group consisting of C1-6 alkyl optionally substituted with one or more, identical or different, substituents R7, wherein one or more methylene(s) of said C1-6 alkyl is optionally and individually replaced with -O- or C=O; C3-6 cycloalkyl optionally substituted with one or more, identical or different, substituents R7; and tetrahydropyranyl; wherein two R7 are optionally linked together to form a ring together with the intervening atom(s); R7 is individually selected from C1-3 alkoxy optionally substituted with one or more F; -OH; -O-benzyl; C1-3 alkyl optionally substituted with OH; N(CH3)2; N(H)2; ; and ; or when two R7 are linked together to form a ring, then said two R7 are individually selected from C1-2 alkanediyl optionally substituted with one or two substituents selected from F and OH, and one of the methylene of said C1-2 alkanediyl is optionally replaced with -O-; orR5 and R6 are linked together to form a ring andR5is a bond or C1-5 alkanediyl optionally substituted with one or more, identical or different, substituents R8, and one methylene of the C1-5 alkanediyl is optionally replaced with -O- or N(R9); andR6is a bond or C1-5 alkanediyl optionally substituted with one or more, identical or different, substituents R8, and one methylene of the C1-5 alkanediyl is optionally replaced with -O- or N(R9); wherein two R8 are optionally linked together to form a ring together with the intervening atom(s); R8 is individually selected from C1-3 alkyl optionally substituted with OH; -OH; F; N(H)2; and -OC1-3 alkyl optionally substituted with one or more F; or when two R8 are linked together to form a ring, then said two R8 are individually selected from C1-3 alkanediyl optionally substituted with one or two substituents selected from F, OH, and NH2, and one or two methylene(s) of said C1-3 alkanediyl is optionally and individually replaced with -O-, -N(H)- or -N(CH3)-; andR9 is H, C1-3 alkyl, oxetanyl, or , or a pharmaceutically acceptable salt thereof, for use in treating, alleviating or preventing diseases and disorders related to the activity of WNK1. 23. The compound according to any one of claims 1-19, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 20, for use in treating, alleviating or preventing diseases and disorders related to the activity of WNK1.  24. The compound for use according to claim 21 or 22, wherein the disease or disorder related to the activity of WNK1 is hypertension.  25. The compound for use according to claim 21 or 22, wherein the disease or disorder related to the activity of WNK1 is cancer.  26. The compound for use according to claim 24, wherein the cancer is selected from leukemia, lymphoma and myeloma.  27. Use of a compound according to any one of claims 1-19, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 20, for the manufacture of a medicament for treating, alleviating or preventing diseases and disorders related to the activity of WNK1.  28. A method for treating, alleviating or preventing diseases and disorders related to the activity of WNK1, said method comprising administering a compound according to any one of claims 1-19, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 20, to a subject in need thereof.  

Images